Adam King - Mar 3, 2022 Form 4 Insider Report for QSAM Biosciences, Inc. (QSAM)

Role
Chief Financial Officer
Signature
/s/ Adam King
Stock symbol
QSAM
Transactions as of
Mar 3, 2022
Transactions value $
$0
Form type
4
Date filed
6/29/2023, 06:14 AM
Next filing
May 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction QSAM Common Stock Award $0 +20.9K $0.00 20.9K Jun 23, 2023 Direct F1
transaction QSAM Common Stock Award +2.04K +9.76% 23K Jun 23, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QSAM Options to buy common stock Award $0 +12.5K $0.00 12.5K Mar 3, 2022 Common Stock 12.5K $10.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This award of shares is being made pursuant to the Issuer's restricted stock award agreement and is subject to a vesting schedule, such that a portion or all of this award of restricted stock may be forfeited in the future if certain milestones are not met.
F2 Shares acquired upon conversion of deferred salary of $10,200.
F3 As of 3/31/2023, 9,375 shares vested based on performance. The balance of the shares will vest in 36 monthly installments commencing March 1, 2023.